NeoGenomics (MEX:NEO) Cyclically Adjusted PB Ratio: (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NEO NeoGenomics Inc MEX:NEO
71 GF Score
Price MXN176.40
GF Value MXN219.97
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is NeoGenomics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


NeoGenomics  (MEX:NEO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


NeoGenomics Cyclically Adjusted PB Ratio Related Terms


NeoGenomics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for NeoGenomics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics Cyclically Adjusted PB Ratio Chart

NeoGenomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.85 2.23 3.24 2.87 1.85

NeoGenomics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.19 1.22 1.85 1.13 0.00

MEX:NEO vs WGS, CDNA, PSNL: Cyclically Adjusted PB Ratio Comparison

For the Diagnostics & Research subindustry, NeoGenomics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics Cyclically Adjusted PB Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Cyclically Adjusted PB Ratio falls into.


MEX:NEO
71GF Score
NeoGenomics Inc MEX:NEO
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeoGenomics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

NeoGenomics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, NeoGenomics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=104.793/333.9520*333.9520
=104.793

Current CPI (Jun. 2026) = 333.9520.

NeoGenomics Quarterly Data

Book Value per Share CPI Adj_Book
201609 49.461 241.428 68.416
201612 42.961 241.432 59.424
201703 40.076 243.801 54.895
201706 38.480 244.955 52.461
201709 38.292 246.819 51.810
201712 41.973 246.524 56.858
201803 38.908 249.554 52.067
201806 39.526 251.989 52.382
201809 61.067 252.439 80.786
201812 66.606 251.233 88.536
201903 65.915 254.202 86.594
201906 90.599 256.143 118.120
201909 94.213 256.759 122.538
201912 91.331 256.974 118.690
202003 112.360 258.115 145.373
202006 136.788 257.797 177.196
202009 132.606 260.280 170.140
202012 123.229 260.474 157.991
202103 147.232 264.877 185.627
202106 186.285 271.696 228.970
202109 189.779 274.310 231.042
202112 183.189 278.802 219.426
202203 171.617 287.504 199.343
202206 167.039 296.311 188.258
202209 160.998 296.808 181.146
202212 153.312 296.797 172.505
202303 138.087 301.836 152.780
202306 128.931 305.109 141.119
202309 129.680 307.789 140.703
202312 125.477 306.746 136.606
202403 120.259 312.332 128.583
202406 131.239 314.175 139.500
202409 139.643 315.301 147.903
202412 146.856 315.605 155.393
202503 141.578 319.799 147.844
202506 124.966 322.561 129.379
202509 119.314 324.800 122.676
202512 116.777 324.054 120.344
202603 115.267 330.213 116.572
202606 104.793 333.952 104.793

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is NeoGenomics (MEX:NEO) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued. The current stock price of MXN176.40 is trading 19.8% below its estimated GF Value™ of MXN219.97. GuruFocus considers NeoGenomics to be Modestly Undervalued.

Key valuation signals for MEX:NEO:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: MXN219.97 vs. price of MXN176.40 (19.8% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the MEX:NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NeoGenomics Business Description

Other Exchanges NEO:USANG9:Germany
Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
71GF Score

Get the complete analysis for MEX:NEO

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN176.40
Price
MXN219.97
GF Value